These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 19535993)
1. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. Waxman EA; Covy JP; Bukh I; Li X; Dawson TM; Giasson BI J Neuropathol Exp Neurol; 2009 Jul; 68(7):785-96. PubMed ID: 19535993 [TBL] [Abstract][Full Text] [Related]
2. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941 [TBL] [Abstract][Full Text] [Related]
3. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. Higashi S; Moore DJ; Yamamoto R; Minegishi M; Sato K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Emson PC; Wada K; Dawson VL; Dawson TM; Arai H; Iseki E J Neuropathol Exp Neurol; 2009 Sep; 68(9):994-1005. PubMed ID: 19680143 [TBL] [Abstract][Full Text] [Related]
4. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Qing H; Zhang Y; Deng Y; McGeer EG; McGeer PL Biochem Biophys Res Commun; 2009 Dec; 390(4):1229-34. PubMed ID: 19878656 [TBL] [Abstract][Full Text] [Related]
5. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827 [TBL] [Abstract][Full Text] [Related]
6. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Uryu K; Richter-Landsberg C; Welch W; Sun E; Goldbaum O; Norris EH; Pham CT; Yazawa I; Hilburger K; Micsenyi M; Giasson BI; Bonini NM; Lee VM; Trojanowski JQ Am J Pathol; 2006 Mar; 168(3):947-61. PubMed ID: 16507910 [TBL] [Abstract][Full Text] [Related]
7. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152 [TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389 [TBL] [Abstract][Full Text] [Related]
9. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991 [TBL] [Abstract][Full Text] [Related]
10. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. Tanaka M; Kim YM; Lee G; Junn E; Iwatsubo T; Mouradian MM J Biol Chem; 2004 Feb; 279(6):4625-31. PubMed ID: 14627698 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and pathological characterization of Lrrk2. Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584 [TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396 [TBL] [Abstract][Full Text] [Related]
14. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions. Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220 [TBL] [Abstract][Full Text] [Related]
15. LRRK2 and neurodegeneration. Santpere G; Ferrer I Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648 [TBL] [Abstract][Full Text] [Related]
17. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653 [TBL] [Abstract][Full Text] [Related]
18. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595 [TBL] [Abstract][Full Text] [Related]
19. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Covy JP; Giasson BI Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487 [TBL] [Abstract][Full Text] [Related]
20. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]